Wednesday, June 15, 2005

Listening to Prozac? How about Listening to Women?



I started this blog to work on my book and today, by gum, I am going to write a post that is dedicated to this end. So, here it is:


"Imagine that we have to hand a medication that can move a person from a normal
psychological state to another normal psychological state that is more desired
or better socially rewarded." --Peter Kramer

In 1993, Peter Kramer published Listening to Prozac, a book intended to draw ethicists into debating the ethical implications of Selective Serotonin Re-Uptake Inhibitors (SSRIs), which were the new generation of antidepressants gaining recognition among psychopharmacologists. Kramer's most provocative thesis is to defend "cosmetic psychopharmacology" as an ethically permissible psychiatric practice. Prozac, according to Kramer, is no mere antidepressant; rather, what we have here is a powerful drug that patients who are not afflicted with depression can use to make themselves "better than well." Prozac promises to transform brooding, socially awkward persons into peppy and popular ones. More importantly, prescribing this drug to the non-afflicted does not transgress the proper boundaries of psychiatric practice.

As Kramer hoped, ethicists and psychiatrists responded to his challenge with both applause and horror. In bioethics circles, which is the arena I am mostly concerned with, the Prozac debate has evolved into a debate over the line between "treatment" and "enhancement," and how new technologies radically rewrite the cultural narrative on depression. While a fringe of anti-psychiatrists will always linger who will question the very legitimacy of the profession in general and specifically any therapeutic intervention, for the most part no one involved in this debate has any serious qualms about the emergence of drug therapy for treating mental illness. Instead, the debate centers on what constitutes clinical depression, that is drawing the line between the kind of "depression" that warrants medical treatment and the kind that is a by-product of our all-too-human nature.

Arguing against Kramer's defense of cosmetic psychopharmacology are the "psychopharmacological Calvinists," who generally find some cultural and personal value in experiences of depression. Prozac, they argue, robs depression sufferers of important insights. Or, it interrupts processes crucial to our moral development--an experience which the first-rate thinker John Stuart Mill credited as transforming his ideas about pleasure, which benefitted all humankind.

On the other hand, the "psychopharmacological Hedoninsts,"--Kramer prominent among them--consistently point out the old-fashioned and romantic ideas to which these Calvinists cling. To still believe that bouts of depression offer us a "special perspective" belies another uncritical belief: that moods are more than neurochemical patterns that color our perceptions of the world. We are each born with a given temperament, a neurochemical profile, that may or may not be valued by the larger culture. Kramer writes
"certain dispositions now considered awkward or endearing, depending on taste,
might be seen as ailments to be pitied and, where possible, corrected. Tastes
and judgments regarding personality styles do change. The romantic, decadent
stance of Goethe's young Werther or Chateaubriand's Rene we now see as merely
immature, overly depressive, perhaps in need of treatment. Might we not, in a
culture where overseriousness is a medically correctable flaw, lose our taste
for the melancholic or brooding artists--Schubert, or even Mozart in many of his
moods?" (Kramer 1993, 20).


Hence the Prozac debate pits the rather romantic ethicists and psychiatrists, who want to preserve a long standing view that depression can be culturally valuable, against the rather unromantic ethicists and psychiatrists, who decode the mysteries of mood into neurochemistry.

And, I think these ethicists have the debate all wrong. The Prozac debate is primarily a debate over which gender traits our culture prefers: competitive, productive, and energetic "masculinity" over self-effacing, unassuming, and irritating "femininity." Both of these camps of the Prozac debate fail to take seriously how cultural preferences for idealized masculinity play out in both the diagnosis and treatment of depression. While the calvinists and hedonists debate the importance of depressive temperaments to art and philosophy, the majority of Prozac prescriptions are written to anxious and overwhelmed women, who have been bombarded by a marketing campaign that trains women to see themselves as ill. Our cultural burden of worshiping wise melancholic men is once again directing our cultural energies toward eradicating the problem of mad depressed women.

5 comments:

  1. You are off to a damn fine start! Clear, to the point, and compelling. You, go, grrrlll, straight to a book tour!

    ReplyDelete
  2. But women can still be clinically depressed, right? This doesn't have to do with depression, but I think it's relevant: when I was a young child, my mother was perpetually exhausted. On many days she couldn't get out of bed. When she went to the doctor she would be told, of course you're tired, you've got 5 kids! This continued for years. For about a decade, she lived her life in a complete fog. Then a doctor did some tests and found she had a thyroid deficiency. She started taking medication and voila, good as new. Likewise, I know many women who were in terrible shape, but were cured by antidepressants. So I'm saying just because a lot of women take antidepressants who don't really need them, doesn't mean they aren't a crucial medication for a lot of other women.

    ReplyDelete
  3. Maynard--

    Certainly women can be clinically depressed. And, if presented with good, scientific evidence that they got "clinically depressed" more often than men, I wouldn't bristle. In fact, I don't have any problem with seeking out medical help, taking pills, or whatever. I am all for solutions!

    I am trying to differentiate my arguments from the "calvinists." I also think that the "hedonists" tend to overshoot, in an effort to discredit the "calvninists." I am less concerned with the technological developments in psychiatry as I am with the attitude that we can tinker with temperament to suit what is more likely to be socially rewarded. That seems problematic when we are trying to erase "feminine" traits (this is similar to pro-choice women being outraged at the high rates of "feticide" of females in India). The motivations are suspect.

    Sometimes psychiatrists who embrace the SSRIs argue that the drugs have taught us to better identify depression. But, believe me, there are some serious scientific issues here. Finding a drug that allows you to alter peoples' temperaments, and then deciding that in fact, their tempermants were actually "abnormal" is an odd way to do diagnosis. (Which is how even Kramer argues at times--especially in his new book). Here you are experminenting with drugs and then making clinical decisions (not to mention classification decisions) based on the effects of the drug on behavior. Isn't that putting the cart before the horse?

    And, of course, my particular issue with this "cosmetic psychopharmacology" issue is that it disproportionately targets women (pay attention to the drug ads--I will certainly be posting some here). The pharmaceutical industry is selling directly to women, based on diagnoses that are a bit shaky because they are determined by the effects of the drug on personality.

    But there are even more problems: the early clinical trials of SSRIs showed that they were NOT effective in treating severe depressions, only mild depressions. Moreover, even with mild depressions they are no more effective than placebo treatment.

    So, yes, medical intervention is good. But, is cosmetic psychopharmacology a "medical intervention"?

    ReplyDelete
  4. Anonymous1:57 PM

    Great start---clear and compelling.
    But is it just gender that depression medication is correcting?
    You say:
    The Prozac debate is primarily a debate over which gender traits our culture prefers: competitive, productive, and energetic "masculinity" over self-effacing, unassuming, and irritating "femininity." Both of these camps of the Prozac debate fail to take seriously how cultural preferences for idealized masculinity play out in both the diagnosis and treatment of depression

    But consider the medication of children for depression and related ailments. Much of the time, the children are medicated to perform better in the role of students. So I wonder whether your claim that SSRI's are used to selectively reinforce preferred masculinity needs to be reconsidered in light of the other social roles people are medicated in order to fit.

    ReplyDelete
  5. SF--Thanks!

    Well, I do think that in the case of SSRIs that gender is one of the primary motivations for "stamping out depression." I don't think that it is the only motive in medication. But, this particular medication and ailment are full of uncritically held beliefs about gender and depression (the wise man and mad woman paradigm that I will elaborate).

    Interestingly, in the case of ADHD, you are trying to harness (sp?) the energy of the boy into the more controlled, adult masculine ideal. So, even there you could make a case.

    But, you are right to raise this question. I have to walk a fine line between being merely rhetorical about gender and Prozac and being provocative enought that I am adding something new to the debate. Not easy!

    ReplyDelete